Transenterix Inc (TRXC) Sees Large Increase in Short Interest

Transenterix Inc (NYSEAMERICAN:TRXC) saw a large growth in short interest in the month of December. As of December 29th, there was short interest totalling 15,231,489 shares, a growth of 4.6% from the December 15th total of 14,554,764 shares. Based on an average trading volume of 2,743,340 shares, the short-interest ratio is currently 5.6 days. Approximately 10.4% of the shares of the company are sold short.

Shares of Transenterix (NYSEAMERICAN TRXC) traded down $0.02 during midday trading on Wednesday, hitting $2.01. 1,731,100 shares of the company traded hands, compared to its average volume of 2,431,050. Transenterix has a 12-month low of $0.45 and a 12-month high of $5.00. The firm has a market capitalization of $408.45, a PE ratio of -3.24 and a beta of 2.02.

In other news, insider Todd Pope sold 600,000 shares of the firm’s stock in a transaction on Wednesday, October 18th. The shares were sold at an average price of $3.68, for a total value of $2,208,000.00. Following the completion of the sale, the insider now owns 462,644 shares in the company, valued at approximately $1,702,529.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Joseph P. Slattery sold 333,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $2.93, for a total transaction of $975,690.00. Following the completion of the sale, the chief financial officer now owns 440,974 shares of the company’s stock, valued at approximately $1,292,053.82. The disclosure for this sale can be found here. Insiders sold a total of 1,462,609 shares of company stock valued at $4,666,595 in the last 90 days.

A hedge fund recently raised its stake in Transenterix stock. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Transenterix Inc (NYSEAMERICAN:TRXC) by 87.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 79,150 shares of the medical instruments supplier’s stock after acquiring an additional 37,000 shares during the period. Ladenburg Thalmann Financial Services Inc. owned about 0.05% of Transenterix worth $113,000 at the end of the most recent reporting period.

Several brokerages recently commented on TRXC. Stifel Nicolaus raised their price objective on shares of Transenterix from $3.75 to $4.00 and gave the company a “buy” rating in a research note on Tuesday, October 31st. BTIG Research reiterated a “hold” rating on shares of Transenterix in a research note on Monday, December 18th. Finally, Ladenburg Thalmann Financial Services set a $5.00 price objective on shares of Transenterix and gave the company a “buy” rating in a research note on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. Transenterix currently has an average rating of “Hold” and an average price target of $2.61.

TRADEMARK VIOLATION NOTICE: “Transenterix Inc (TRXC) Sees Large Increase in Short Interest” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/10/transenterix-inc-trxc-sees-large-increase-in-short-interest.html.

About Transenterix

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Receive News & Ratings for Transenterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply